Enveric Biosciences Advances Non-Hallucinogenic DMT Analog Drug With Promising Preclinical Results [Benzinga]
Monday, November 25, 2024 1 min read
Key Takeaway: Enveric Biosciences has successfully completed preclinical pharmacokinetic studies for its drug candidate EB-003, which is designed to treat depression and anxiety without inducing hallucinations. This non-hallucinogenic DMT analog shows promise in addressing mental health issues while minimizing side effects associated with traditional psychedelics. The focus on neuroplasticity highlights its innovative approach.
Price reaction · baseline $59.994 (2024-11-22 close) · hit pre-market · clean, no other ENVB news in the window
day 0 close
-3.4%
day 1
-1.9%
day 3
-1%
Market Sentiment Analysis
POSITIVE FACTORS
Enveric Biosciences has advanced its drug candidate EB-003.
The drug aims to treat depression and anxiety effectively.
EB-003 is non-hallucinogenic, reducing potential side effects.
Full Press Release Details
Psychedelics biotech company Enveric Biosciences completed preclinical pharmacokinetic (PK) studies for its leading drug candidate EB-003 aimed at treating depression and anxiety without causing hallucinations. EB-003 is a neuroplastic and non-hallucinogenic N, N-Dimethyltryptamine (DMT) analog drug candidate., such as ataxia or hyperthermia.
Full Article >>
Frequently Asked Questions
What is EB-003?
EB-003 is a non-hallucinogenic DMT analog drug candidate aimed at treating depression and anxiety.
What are the benefits of EB-003?
EB-003 is designed to treat mental health issues without causing hallucinations, minimizing side effects.
What studies has Enveric completed?
Enveric Biosciences has completed preclinical pharmacokinetic studies for EB-003.
What conditions does EB-003 target?
EB-003 targets depression and anxiety in patients.